Full video transcriptClick to expand
Auto-generated transcript of @breannekallonen's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00For patients who are considering coming off of semaglutides like wasembe,
- 0:03here's the checklist that I run through with them before they do. This usually happens when they
- 0:08are about five to ten pounds away from their goal weight. And before I get a whole bunch of
- 0:12comments, if you are working with your family physician to stay on this medication long term,
- 0:16that's absolutely okay. This is for individuals who want to come off or are planning on coming off.
- 0:21These are the things that I check with patients and I found when these things are under control or
- 0:26dialed in, weight loss is maintained and the patients do really well. The first thing that I
- 0:31believe is that weight is not the only pre-determining factor of health. We need to be utilizing medications
- 0:38as a tool to encourage a healthy lifestyle. So why want to dial in your nutrition? How many
- 0:44grams of fiber are you consuming on a daily basis? I have patients tractors so we can be on the same
- 0:48page and make recommendations. How many grams of protein are you getting on a daily basis? Does
- 0:52your nutrition plan feel easy? Does it feel enjoyable? Are you eating at consistent times?
- 0:59Have you reduced the late night snacking? How is your sleep? How is your mental health? How are
- 1:04your stress levels? These are all things that are particularly important. I then ask about exercise.
- 1:10Have you put in and created a habit when it comes to some sort of movement? It doesn't mean that you
- 1:17have to go to the gym for an hour in a day. But in terms of the individuals who have a really
- 1:22great quality of life, when they are in their 70s, 80s, 90s, they have developed a sustained lean
- 1:28muscle mass. So I want patients to be doing some sort of movement, some sort of activity, even if
- 1:33it's 20 minutes, three times a week of a YouTube video. Now you're in the habit of doing it. That's
- 1:39what I want to see. I also want to ensure that individuals are taking a fiber-based supplement
- 1:45so that they can get in the habit of taking this prior to discontinuing or reducing the medication.
- 1:50Now one of the reasons why I like to do this and I recommend proplamanid fiber is to control
- 1:56for appetite. Taking fiber before your meal not only helps with appetite but has been shown to help
- 2:02cholesterol management and manage your blood sugar. The underlying issue for a lot of these
- 2:06individuals with resistant weight loss is insulin resistance so the fiber can help there. For some
- 2:11patients who have a really strong genetic predisposition to insulin resistance and pre-diabetes,
- 2:16we may also be considering the verbal-based supplement called berberine. Fiber, berberine,
- 2:23and if you're not getting enough protein, maybe an amino acid or a protein powder.
- 2:27Then we have a look at the blood work. Where is the hemoglobin A1C? Where is the fasting insulin?
- 2:31Where are the hormones? Where are the cortisol levels? Where is the thyroid? Just to make sure
- 2:35everything is great so that the patient can be successful when they choose to stop the medication.
Coming off Ozempic: what the evidence says about stopping GLP-1s
Quick answer
Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al. withdrawal trial. The creator's checklist of lifestyle stabilization, metabolic bloodwork, and supplement support before stopping is clinically reasonable as a framework, but the supporting evidence for supplements like berberine preventing post-GLP-1 regain specifically is not established in controlled trials. Patients considering discontinuation should have a documented plan with their prescribing clinician, not derive one from social media content.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Coming off Ozempic: what the evidence says about stopping GLP-1s, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Coming off Ozempic: what the evidence says about stopping GLP-1s" from Dr Breanne Kallonen ND. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al.
The reason this review is not generic is the source wording and the canonical claim label "glp1 if you are planning to come off ozempic here is what to cons." In this clip, the useful excerpt is: "For patients who are considering coming off of semaglutides like wasembe, here's the checklist that I run through with them before they do." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide discontinuation is associated with significant weight regain driven by the return of appetite-regulating hormones to pre-treatment baseline, as documented in the 2022 Wilding et al. withdrawal trial. The creator's checklist of lifestyle stabilization, metabolic bloodwork, and supplement support before stopping is clinically reasonable as a framework, but the supporting evidence for supplements like berberine preventing post-GLP-1 regain specifically is not established in controlled trials. Patients considering discontinuation should have a documented plan with their prescribing clinician, not derive one from social media content.
- Wilding et al. (2022) found patients regained approximately two-thirds of weight within 12 months of stopping semaglutide, even with continued lifestyle support.
- Psyllium fiber supplementation has documented evidence for modest improvements in postprandial blood sugar and LDL cholesterol (Gibb et al., 2016, AJCN), making it a reasonable add-on but not a GLP-1 replacement.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Wilding et al. (2022) found patients regained approximately two-thirds of weight within 12 months of stopping semaglutide, even with continued lifestyle support.
- Psyllium fiber supplementation has documented evidence for modest improvements in postprandial blood sugar and LDL cholesterol (Gibb et al., 2016, AJCN), making it a reasonable add-on but not a GLP-1 replacement.
- Berberine is not FDA-approved for insulin resistance or pre-diabetes and should not be treated as an equivalent to metformin or a clinical substitute for GLP-1 therapy.
- A pre-discontinuation bloodwork panel covering HbA1c, fasting insulin, thyroid, and hormones is clinically sound practice and can identify metabolic factors that may increase regain risk.
- Lean muscle mass preservation through resistance or aerobic exercise has strong independent evidence for functional longevity, regardless of GLP-1 status (Cruz-Jentoft et al., 2019, Age and Ageing).
- No published RCT has demonstrated that a fiber-berberine-protein-exercise protocol reliably prevents weight regain after GLP-1 discontinuation; the creator's confidence here exceeds the available data.
- Any decision to stop or taper a GLP-1 medication should be made with the prescribing clinician, not based on a social media checklist, however well-intentioned.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @breannekallonen actually say?
The creator, identifying as a functional medicine practitioner in Ontario, laid out a pre-discontinuation checklist for patients coming off semaglutide. The list covers nutrition habits (fiber and protein intake), exercise consistency, supplement use (psyllium fiber and berberine), and bloodwork including HbA1c, fasting insulin, hormones, cortisol, and thyroid markers. She frames semaglutide as "a tool" and focuses on whether lifestyle habits are stable enough to sustain results without the medication. She also flags insulin resistance as the root driver for many patients with resistant weight loss, and recommends berberine for those with strong genetic predisposition to insulin resistance or pre-diabetes.
The tone is measured. She explicitly says staying on GLP-1s long-term is fine if that's what a patient and their physician decide. That kind of nuance is rare in this content category.
Does the science back this up?
Mostly, yes, with some important caveats. The core concern, that weight regain after stopping semaglutide is significant and tied to lifestyle readiness, is well-documented. The supplement recommendations are where things get shakier.
On regain: a 2022 trial by Wilding et al. in Diabetes, Obesity and Metabolism found that participants regained roughly two-thirds of their lost weight within one year of stopping semaglutide, and appetite and hunger markers returned to near-baseline. This is the single most important data point anyone considering stopping GLP-1s should know. Lifestyle scaffolding matters, but it may not fully compensate for the appetite-suppressing pharmacology the drug was providing.
On psyllium fiber for appetite and blood sugar: solid ground here. A 2016 meta-analysis by Gibb et al. in the American Journal of Clinical Nutrition confirmed psyllium supplementation improves postprandial glucose and insulin response. The appetite effect is real but modest.
On berberine for insulin resistance: the evidence is promising but not definitive. A 2012 meta-analysis by Dong et al. in Evidence-Based Complementary and Alternative Medicine showed berberine reduced fasting glucose comparably to metformin in some populations. However, effect sizes vary widely, bioavailability is poor, and it is not FDA-approved for any indication. Calling it a supplement alternative for people with genetic insulin resistance risk is a stretch without individualized clinical assessment.
What did they get wrong (or right)?
Credit where it's due: framing bloodwork (HbA1c, fasting insulin, thyroid, cortisol) as a pre-discontinuation checkpoint is genuinely good practice. Most clinicians don't do this systematically, and it reflects real clinical thinking about why weight returns after stopping GLP-1s.
The muscle mass point also holds. She references maintaining "sustained lean muscle mass" into older age as a quality-of-life marker. This tracks with data from Bhasin et al. and other sarcopenia literature linking lean mass preservation to functional longevity.
What's weaker: the claim that when these factors are "dialed in, weight loss is maintained" is stated with more confidence than the evidence supports. There is no published RCT showing that a fiber-berberine-protein-exercise protocol reliably prevents regain after GLP-1 discontinuation. That may be her clinical observation, but it shouldn't be presented as an established finding.
The phrase "insulin resistance" is used loosely to describe a broad population. Not every person on semaglutide has clinically significant insulin resistance, and recommending berberine without confirmed metabolic indication is premature.
What should you actually know?
If you are thinking about stopping semaglutide, the regain data should be your first read, not a TikTok checklist. The Wilding 2022 study is public and free to access. The biological drive to regain weight after stopping a GLP-1 agonist is not a willpower failure. It is pharmacology reversing.
The lifestyle habits this creator recommends, consistent protein, fiber intake, structured movement, good sleep, stress management, are legitimate health goals with independent benefits. They are not a guaranteed substitute for the medication's appetite and glycemic effects.
Berberine is not a regulated drug. It is not equivalent to metformin. It is not approved to treat insulin resistance or pre-diabetes. If your clinician is recommending it, ask them what specific bloodwork finding they are responding to and what the monitoring plan is.
The bloodwork panel she recommends is reasonable as a snapshot of metabolic health before discontinuing. But bloodwork alone does not predict whether you will maintain weight loss. Behavior over time does, and even strong behavior may not fully replace what a GLP-1 was doing physiologically.
Work with a licensed prescriber. Do not stop or reduce a GLP-1 medication based on a TikTok video, including this one.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Breanne Kallonen ND · TikTok creator
413.3K views on this video
If you are planning to come off ozempic here is what to consider #bloodwork #functionalmedicine #ontario #hairloss #pcos #hormones #doctorsoftiktok #ozempic #insulinresistance #bloodsugar
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about wilding et al. (2022) found patients regained approximately two-thirds of?
Wilding et al. (2022) found patients regained approximately two-thirds of weight within 12 months of stopping semaglutide, even with continued lifestyle support.
What does the video say about psyllium fiber supplementation has documented evidence for modest improvements in?
Psyllium fiber supplementation has documented evidence for modest improvements in postprandial blood sugar and LDL cholesterol (Gibb et al., 2016, AJCN), making it a reasonable add-on but not a GLP-1 replacement.
What does the video say about berberine?
Berberine is not FDA-approved for insulin resistance or pre-diabetes and should not be treated as an equivalent to metformin or a clinical substitute for GLP-1 therapy.
What does the video say about a pre-discontinuation bloodwork panel covering hba1c, fasting insulin, thyroid,?
A pre-discontinuation bloodwork panel covering HbA1c, fasting insulin, thyroid, and hormones is clinically sound practice and can identify metabolic factors that may increase regain risk.
What does the video say about lean muscle mass preservation through resistance?
Lean muscle mass preservation through resistance or aerobic exercise has strong independent evidence for functional longevity, regardless of GLP-1 status (Cruz-Jentoft et al., 2019, Age and Ageing).
What does the video say about no published rct has demonstrated?
No published RCT has demonstrated that a fiber-berberine-protein-exercise protocol reliably prevents weight regain after GLP-1 discontinuation; the creator's confidence here exceeds the available data.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Breanne Kallonen ND, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.